Ivabradine provides a targeted approach to heart rate reduction in chronic heart failure, particularly for patients with resting HR ≥75 bpm or those intolerant to beta-blockers.
Answers are grounded in this paper and cite their sources.
Does not support ivabradine adoption in Japanese chronic HF; leaves open efficacy confirmation in larger trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Masaru Hatano (2022) conducted a review in Chronic Heart Failure. Ivabradine and Beta-blockers vs. Placebo / Standard care was evaluated on Cardiovascular death or hospitalization for worsening heart failure (J-SHIFT trial) (HR 0.67, 95% CI 0.40-1.11, p=0.1179).
Synapse has enriched 10 related papers. Consider them for comparative context: